Waters stock steadies after strong Q2 earnings beat and guidance raise

Waters Corp (US9418481035) stock is trading in the low-$410s after the company’s second-quarter 2026 results delivered a clear earnings beat and a higher full-year guidance as of August 10, 2026.

Per a recent earnings overview, Waters reported second-quarter 2026 revenue of $1.65 billion, modestly ahead of analyst estimates of $1.62 billion, with adjusted earnings per share of $3.05 versus expectations of $3.01.

The same overview shows that management lifted its full-year 2026 adjusted EPS guidance to $14.55 at the midpoint, while setting third-quarter 2026 revenue guidance at $1.75 billion, reinforcing the company’s growth narrative despite margin pressure.

Q2 2026 earnings beat and outlook

Second-quarter 2026 is now the key reference point for Waters’ fundamentals, and the numbers highlight both top-line momentum and profitability challenges.

Per an earnings-call recap for Q2 2026, revenue came in at $1.65 billion compared with $1.62 billion expected, translating into a $30 million beat against consensus and 113 percent year-on-year growth for the period.

The same recap notes that adjusted EPS reached $3.05 versus $3.01 forecast, a $0.04 outperformance that underscores resilient demand for Waters’ instruments and services even as operating margin turned negative.

According to that Q2 2026 summary, operating margin for the quarter was -5.2 percent, down from 24.4 percent in the second quarter of 2025, showing that higher costs and strategic investments are weighing on profitability compared with the prior year.

The same source indicates that organic revenue grew 7 percent year-on-year in Q2 2026, highlighting that underlying demand for Waters’ core laboratory products continues to expand even after the post-pandemic normalization in research and industrial spending.

Management also raised full-year 2026 adjusted EPS guidance to $14.55 at the midpoint per the earnings recap, signaling confidence that margin headwinds can be managed while maintaining growth in high-value segments.

For the upcoming third quarter of 2026, the company is guiding for revenue of $1.75 billion at the midpoint, very close to prevailing analyst expectations and suggesting a continued, but measured, growth path through the second half of the year.

Stock reaction and valuation context

Market data for Waters as of August 10, 2026, shows the stock closing at $411.77, up $4.91 or 1.21 percent on that trading day.

The same quote overview notes that Waters shares traded between $404.77 and $416.62 on August 12, 2026, with a last reported price of $415.56, leaving the stock 2.7 percent above that session’s low and 0.3 percent below the high.

According to one recent stock analysis page updated on August 12, 2026, Waters closed at $415.13, gaining $0.13 or 0.03 percent on the day, which positions the shares modestly above the $411.77 level recorded at the August 10, 2026 close.

The same analysis notes that Waters’ market capitalization stood at $40.43 billion in the wake of the Q2 2026 results, giving investors a sense of the company’s scale in the life-sciences tools sector.

A separate quote snapshot indicates that Waters’ market cap is now closer to $45.19 billion at a stock price of $415.56, reflecting the uplift in valuation after the strong revenue and EPS performance.

Per the stock performance history on a major market portal, Waters shares started calendar 2026 at $380.45 and have since risen to around $415.13, a gain of 9.1 percent year-to-date as of August 12, 2026.

That same performance table highlights that the stock is trading meaningfully above its early-year level, showing that investors have rewarded the company’s ability to grow revenue while navigating uneven margins.

From a trading-range perspective, the August 12, 2026 intraday low of $404.77 and high of $416.62 frame the current consolidation zone, with the latest quote near the upper end of this band.

For investors, the combination of a 9.1 percent year-to-date gain, a mid-$400s share price and a market cap exceeding $40 billion positions Waters as a mature growth story rather than a speculative small-cap.

Margin pressure versus growth momentum

The sharp swing in operating margin between the second quarter of 2025 and the second quarter of 2026 is one of the most striking elements of Waters’ latest report.

In Q2 2025, operating margin stood at 24.4 percent, while the Q2 2026 figure dropped to -5.2 percent, representing a deterioration of 29.6 percentage points year-on-year.

This contrast shows that even with strong revenue growth and an EPS beat, cost pressures, restructuring charges or other expenses significantly altered the profitability profile over the past year.

The earnings recap suggests that organic revenue increased 7 percent on a year-on-year basis in Q2 2026, providing a buffer against these margin challenges and underscoring that the demand environment remains favorable.

From a guidance standpoint, management’s decision to raise full-year 2026 adjusted EPS to $14.55 at the midpoint indicates that they see room to improve margins or achieve operating leverage as the year progresses.

When combined with the Q3 2026 revenue target of $1.75 billion at the midpoint, this guidance paints a picture of continued expansion in Waters’ end markets, including pharma, biotech, and industrial customers.

Investors are likely to watch closely how the company balances investment in innovation and capacity with the need to restore operating margins closer to historical levels.

One key lens for that balance will be the trajectory of adjusted EPS in the coming quarters, given the new full-year target and the recent Q2 2026 beat.

Analyst expectations and earnings trends

Earnings-trend data for Waters’ current fiscal year offers additional context beyond the headline Q2 2026 figures.

Per an earnings overview that breaks down recent quarters, Waters’ first quarter of fiscal 2026 generated revenue of $1.27 billion alongside a net loss of $72 million.

That Q1 2026 mix of solid sales with a negative earnings figure set the stage for the stronger profitability performance in Q2 2026, where adjusted EPS came in at $3.05 and beat consensus.

The Q2 2026 report itself shows that actual revenue of $1.65 billion exceeded the $1.62 billion analyst estimate by $30 million, while adjusted EPS of $3.05 was $0.04 ahead of the $3.01 forecast.

This consistent pattern of modest outperformance versus consensus suggests that analysts have adjusted their models to reflect Waters’ growth trajectory but still leave room for incremental beats.

The new full-year 2026 adjusted EPS guidance of $14.55 at the midpoint, as stated in the Q2 2026 commentary, now serves as a central benchmark for both management and the analyst community.

A separate article discussing the most interesting analyst questions from Waters’ Q2 2026 earnings call emphasizes that revenue guidance for Q3 2026 at $1.75 billion is aligned with the Street’s expectations.

That alignment implies that the key debates now revolve less around top-line growth and more around margin recovery, regulatory dynamics, and regional trends such as performance in China.

The same Q2 2026 call recap highlights that organic revenue growth of 7 percent year-on-year is evidence that Waters’ core businesses retain healthy momentum, even as reported operating margin reflects significant near-term pressure.

For investors tracking earnings revisions, the slightly higher full-year EPS guidance could translate into gradual upward adjustments to consensus estimates if execution stays on track through the second half of 2026.

Regulatory filings and reporting cadence

Waters’ reporting cadence is also visible in recent regulatory filings.

According to a filings summary page that tracks Waters’ submissions, the company’s most recent Form 10-Q was filed on August 11, 2026.

This Form 10-Q represents a quarterly update for 2025, reflecting that Waters continues to provide detailed disclosure alongside its regular earnings releases.

The filings page indicates that the latest quarterly filing aligns with the pattern of periodic reporting and offers investors a deeper look at segment performance, cash flows and risk factors.

While the Q2 2026 earnings figures are central for short-term trading decisions, these filings support the broader assessment of Waters’ financial health and strategic priorities.

For long-term shareholders, the combination of timely SEC filings and clear guidance for 2026 provides both transparency and a framework for evaluating management’s execution.

Key products supporting growth

Waters’ financial profile is underpinned by a portfolio of analytical instruments and consumables used in laboratories worldwide.

The company’s core offerings include liquid chromatography systems, mass spectrometry platforms, and related software that help customers analyze complex chemical and biological samples.

Demand for these systems is closely tied to pharmaceutical development, quality control in manufacturing, environmental testing and academic research.

In second-quarter 2026, the reported 7 percent organic revenue growth suggests that these core products, along with service contracts and consumables, continued to see healthy adoption across key end markets.

Waters also generates revenue from upgrades and replacement cycles as customers modernize legacy laboratory infrastructure to meet stricter regulatory requirements and expand capacity.

In its Q2 2026 commentary, the company indicated that ongoing challenges in regions such as China are being managed while it raises full-year guidance, hinting at diversified geographic exposure beyond any single market.

For investors, the product mix matters because high-value instruments and associated consumables can deliver recurring revenue and support margin improvement as volumes grow.

Over time, the balance between hardware sales, consumables, and service contracts will influence both revenue stability and the trajectory of adjusted EPS.

Shares and latest price signal

Waters stock currently trades on the New York Stock Exchange under the ticker WAT, with the most recent closing price of $411.77 as of August 10, 2026, at 4:00 p.m. ET.

Intraday data for August 12, 2026, shows that the shares moved within a range of $404.77 to $416.62, with a last quote around $415.56, underscoring that the stock is holding close to its recent highs following the Q2 2026 earnings beat.

Read more

Further details on Waters’ second-quarter 2026 earnings performance, guidance and market reaction are available via recent earnings-call commentary and real-time quote pages that track the WAT listing on the New York Stock Exchange.

Representative product

One representative example from Waters’ portfolio is its high-performance liquid chromatography systems, which are used by pharmaceutical and research laboratories to separate and analyze compounds with high precision.

Stock and quote snapshot

As of August 10, 2026, at 4:00 p.m. ET, Waters stock closed at $411.77 on the New York Stock Exchange in U.S. dollars, reflecting the market’s response to the company’s recent earnings trajectory.

Fact box

Company: Waters Corp

ISIN: US9418481035

Ticker: WAT

Exchange: New York Stock Exchange

Price (as of August 10, 2026, 4:00 p.m. ET): $411.77 USD

Market cap: $40.43 billion (as of August 10, 2026)

Sector / Industry: Life sciences tools and services

Index membership: S&P 500